Considering the modulation of the IFN pathway as a potential therapeutic target for treating PAH, this holds promising implications for guiding future treatments, prevention strategies, and the development of vaccines for individuals with concurrent HIV-1 and PAH. The gene discussed is IFNA1; the disease is pulmonary arterial hypertension.